ALX Oncology Prices $150 Mln Offering Of Shares And Pre-funded Warrants

ALX Oncology priced an underwritten offering of 76.98 million common shares at $1.57 and pre-funded warrants to purchase 18.57 million shares at $1.569, expected to generate approximately $150 million in gross proceeds and close on or about Feb. 2, 2026. Net proceeds are earmarked to fund clinical development of Evorpacept and the ALX2004 program and for general corporate purposes; the stock has traded between $0.4040 and $2.27 over the past year, closed Friday at $1.74 (+10.83%) and was $1.71 in after-hours trade (-1.72%).

Analysis

Market structure: ALXO’s $1.57 offering (76.98M shares + 18.57M pre-funded warrants = 95.55M potential new shares) injects a meaningful supply overhang versus a thin free float, so near-term selling pressure is likely even though the market initially cheered the de-risking. The $150M proceeds materially reduce short-term financing risk and should push the probability of bankruptcy/near-term dilution lower, shifting optionality from solvency risk to clinical binary risk for Evorpacept and ALX2004.

Risk assessment: Tail risks remain dominated by clinical failure or regulatory setbacks—single negative Phase readout would still wipe out most equity value. Assuming a cash burn range of $10–20M per quarter (industry-consistent for Phase II activity), the raise likely funds operations for ~2–4 years, so the next meaningful valuation drivers are clinical data and enrollment milestones over the 6–24 month window.

Trade implications: Expect immediate softness around the Feb 2 close as new shares and warrant exercises create supply; implied volatility in ALXO options should rise. Tactical plays: capitalize on post-close drift with put spreads or small short position if ALXO breaks below the offering price $1.57; conversely, fundamental buyers who trust the science can take small long exposures on pullbacks below $1.40 targeting >50% upside on positive data within 6–12 months.

Contrarian angles: The market’s 10% intraday rally priced de-risking over dilution—this may be overdone if the company still faces slow enrollment or unclear endpoints. Pre-funded warrants indicate investors wanted immediate equity economics; if many warrants are exercised quickly, mechanical dilution could further depress the stock—monitor warrant exercise timing as a binary trigger within 30–90 days.

Key Decisions for Investors

• Establish a tactical short via Jun-2026 put spread on ALXO sized 0.5–1.0% of portfolio: buy Jun-2026 $1.50 puts and sell $0.75 puts if available, or equivalent strikes; initiate if ALXO trades ≤ $1.57 (offering price) within 1–4 weeks post-close.
• Consider a speculative long (1–2% position) in ALXO common stock only on confirmed close of the offering and share-price pullback to ≤ $1.40; set hard sell target of $3.00 or stop-loss at $0.80, horizon 6–12 months tied to next clinical readout.
• Implement a market-neutral pair: long ALXO / short XBI equal-dollar (size 0.5–1% net exposure) to isolate idiosyncratic clinical upside while hedging sector beta for 3–9 months; rebalance if XBI moves >10% relative to ALXO.
• Reduce small-cap biotech exposure by 2–3% and rotate into large-cap, diversified biopharma (e.g., PFE, MRK) with >18 months runway if cross-sector downside emerges; monitor ALXO 8-Ks for warrant exercise timing and quarterly burn disclosures within 30–60 days as triggers for re-sizing.